Instances for the Recoverable Robust Two-Level Network Design Problem

We provide the instances used in the paper "The Recoverable Robust Two-Level Network Design Problem", by E. Alvarez-Miranda, I. Ljubic, S. Raghavan and P. Toth, accepted for publication in the INFORMS J. on Computing, 2014 (http://dx.doi.org/10.1287/ijoc.2014.0606). This repository contains both the instances used in the paper as well as the results obtained by the proposed algorithm

Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer

The aberrant overexpression of alpha satellite DNA is characteristic of many human cancers including prostate cancer; however, it is not known whether the change in the alpha satellite RNA amount occurs in the peripheral tissues of cancer patients, such as blood. Here, we analyse the level of intracellular alpha satellite RNA in the whole blood of cancer prostate patients at different stages of disease and compare it with the levels found in healthy controls. Our results reveal a significantly increased level of intracellular alpha satellite RNA in the blood of metastatic cancers patients, particularly those with metastatic castration-resistant prostate cancer relative to controls. In the blood of patients with localised tumour, no significant change relative to the controls was detected. Our results show a link between prostate cancer pathogenesis and blood intracellular alpha satellite RNA levels. We discuss the possible mechanism which could lead to the increased level of blood intracellular alpha satellite RNA at a specific metastatic stage of prostate cancer. Additionally, we analyse the clinically accepted prostate cancer biomarker PSA in all samples and discuss the possibility that alpha satellite RNA can serve as a novel prostate cancer diagnostic blood biomarker

A Design Kit for Mobile Device-Based Interaction Techniques

Beside designing the graphical interface of mobile applications, mobile phones and their built-in sensors enable various possibilities to engage with digital content in a physical, device-based manner that move beyond the screen content. So-called mobile device-based interactions are characterized by device movements and positions as well as user actions in real space. So far, there is only little guidance available for novice designers and developers to ideate and design new solutions for specic individual or collaborative use cases. Hence, the potential for designing mobile-based interactions is seldom fully exploited. To address this issue, we propose a design kit for mobile device-based interaction techniques following a morphological approach. Overall, the kit comprises seven dimensions with several elements that can be easily combined with each other to form an interaction technique by selecting at least one entry of each dimension. The design kit can be used to support designers in exploring novel mobile interaction techniques to specic interaction problems in the ideation phase of the design process but also in the analysis of existing device-based interaction solutions

An (MI)LP-based Primal Heuristic for 3-Architecture Connected Facility Location in Urban Access Network Design

We investigate the 3-architecture Connected Facility Location Problem arising in the design of urban telecommunication access networks. We propose an original optimization model for the problem that includes additional variables and constraints to take into account wireless signal coverage. Since the problem can prove challenging even for modern state-of-the art optimization solvers, we propose to solve it by an original primal heuristic which combines a probabilistic fixing procedure, guided by peculiar Linear Programming relaxations, with an exact MIP heuristic, based on a very large neighborhood search. Computational experiments on a set of realistic instances show that our heuristic can find solutions associated with much lower optimality gaps than a state-of-the-art solver.Comment: This is the authors' final version of the paper published in: Squillero G., Burelli P. (eds), EvoApplications 2016: Applications of Evolutionary Computation, LNCS 9597, pp. 283-298, 2016. DOI: 10.1007/978-3-319-31204-0_19. The final publication is available at Springer via http://dx.doi.org/10.1007/978-3-319-31204-0_1

Molecular profiling of cervical cancer progression

Most cancer patients die of metastatic or recurrent disease, hence the importance to identify target genes upregulated in these lesions. Although a variety of gene signatures associated with metastasis or poor prognosis have been identified in various cancer types, it remains a critical problem to identify key genes as candidate therapeutic targets in metastatic or recurrent cancer. The aim of our study was to identify genes consistently upregulated in both lymph node micrometastases and recurrent tumours compared to matched primary tumours in human cervical cancer. Taqman Low-Density Arrays were used to analyse matched tumour samples, obtained after laser-capture microdissection of tumour cell islands for the expression of 96 genes known to be involved in tumour progression. Immunohistochemistry was performed for a panel of up- and downregulated genes. In lymph node micrometastases, most genes were downregulated or showed expressions equal to the levels found in primary tumours. In more than 50% of lymph node micrometastases studied, eight genes (AKT, BCL2, CSFR1, EGFR1, FGF1, MMP3, MMP9 and TGF-β) were upregulated at least two-fold. Some of these genes (AKT and MMP3) are key regulators of epithelial–mesenchymal transition in cancer. In recurrent tumours, almost all genes were upregulated when compared to the expression profiles of the matched primary tumours, possibly reflecting their aggressive biological behaviour. The two genes showing a consistent downregulated expression in almost all lymph node metastases and recurrent tumours were BAX and APC. As treatment strategies are very limited for metastatic and recurrent cervical cancer, the upregulated genes identified in this study are potential targets for new molecular treatment strategies in metastatic or recurrent cervical cancer